06160.HK
BeOne Medicines AG
HKSE · Healthcare · Biotechnology · CH
HKD 220.80
+1.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.1B | 5.4B | 3.8B | 2.5B | 1.4B |
| Cost of Revenue | 746.0M | 787.7M | 594.1M | 379.9M | 1.9B |
| Gross Profit | 5.4B | 4.6B | 3.2B | 2.1B | (511.1M) |
| Operating Expenses | |||||
| R&D Expense | 2.3B | 2.1B | 2.0B | 1.8B | 1.6B |
| SG&A Expense | 2.2B | 2.0B | 1.8B | 1.5B | 1.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 2.7M | 751.0K |
| Total Operating Expenses | 4.5B | 4.1B | 3.8B | 3.3B | 1.3B |
| Cost and Expenses | 5.2B | 4.9B | 4.4B | 3.7B | 3.2B |
| Operating Income (EBIT) | 922.2M | 447.8M | (568.2M) | (1.2B) | (1.8B) |
| Non-Operating | |||||
| Interest Income | 79.0M | 70.6M | 47.8M | 74.0M | 52.5M |
| Interest Expense | 93.1M | 58.3M | — | — | — |
| Net Interest Income | (14.1M) | 12.3M | 47.8M | 74.0M | 52.5M |
| Other Non-Op Income/Expense | (55.0M) | (30.3M) | 35.2M | 381.9M | (171.4M) |
| Non-Operating Income (excl Interest) | (27.2M) | — | — | — | — |
| EBT (Pre-Tax Income) | 867.2M | 417.5M | (533.0M) | (825.8M) | (2.0B) |
| Income Tax Expense | 212.2M | 130.1M | 111.8M | 55.9M | 42.8M |
| Bottom Line | |||||
| Net Income | 655.0M | 287.4M | (644.8M) | (881.7M) | (2.0B) |
| Earnings from Cont. Ops | 655.0M | 287.4M | (644.8M) | (881.7M) | (2.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 655.0M | 287.4M | (644.8M) | (881.7M) | (2.0B) |
| Per Share | |||||
| Basic EPS | HK$0.45 | HK$0.20 | (HK$0.47) | (HK$0.65) | (HK$1.49) |
| Diluted EPS | HK$0.44 | HK$0.20 | (HK$0.47) | (HK$0.65) | (HK$1.49) |
| Revenue Per Share | HK$4.22 | HK$3.77 | HK$2.78 | HK$1.81 | HK$1.06 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.4B | 1.4B | 1.4B | 1.3B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.4B | 1.4B | 1.3B |
| Profitability Metrics | |||||
| EBITDA | 1.1B | 589.7M | (396.4M) | (1.1B) | (1.7B) |
| D&A | 154.8M | 141.9M | 171.8M | 87.7M | 66.3M |
| EBIT | 949.3M | 447.8M | (568.2M) | (1.2B) | (1.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026